Now let me write the final consolidated review.

## Summary

This paper proposes HypoGeneAgent, an LLM-driven framework that uses the consistency of LLM-generated GO annotations across clusters (intra-cluster agreement ICS and inter-cluster distinctiveness ICD) to select clustering resolution. The key idea is that when clusters are biologically meaningful, an LLM's functional descriptions of them will be internally coherent within each cluster and clearly distinct between clusters. The paper includes a Stage 1 benchmark evaluating multiple LLMs, embeddings, and prompts on curated GOBP gene sets, and a Stage 2 application to K562 Perturb-seq data. The Resolution Score selects r=0.4 at the GEX level and r=0.5 at the perturbation level.

## Strengths

- **Novel conceptual framing.** Using annotation consistency as a criterion for resolution selection is genuinely underexplored (Section 3.4, lines 75–80). Prior work (Hu et al. 2025, GeneAgent Wang et al. 2025) used LLMs only for post-hoc annotation; closing the loop back to clustering hyperparameters is a reasonable and interesting direction.

- **Clean metric formalization.** ICS, ICD, and the Resolution Score are clearly defined (Table 1, lines 57–64; lines 75–80). The decomposition into intra-cluster coherence and inter-cluster distinctiveness is intuitive and easy to adopt.

- **Useful Stage 1 benchmark.** The systematic evaluation of multiple LLMs (GPT-4o, GPT-o3, GPT-5, Gemini-2.0-flash, Gemini-2.5-pro), embedding methods, prompt variants, and temperature settings on curated GOBP gene sets (Section 4.3, lines 187–200) provides a practical design space exploration for gene-set annotation.

## Weaknesses

### Major

- **Central claim of superior resolution selection is not validated against any biological ground truth.** The paper repeatedly asserts that its selected resolution "exhibits alignment with known pathway" (abstract) and "recovers known perturbation effects better than modularity and silhouette criteria" (line 25) and "matched known perturbation biology" (line 261). However, no external biological ground truth (e.g., known perturbation classes, cell-type labels, or pathway annotations from the Replogle et al. 2022 dataset) is used to quantitatively compare resolutions. The "comparison" with silhouette and modularity (Section 4.4) simply shows that different metrics pick different values. Claiming superiority from this is logically unsupported — the paper can only report *what* resolution it selects, not that its selection is *better*. Since resolution selection is the paper's headline contribution, this evidential gap undermines the core claim. The K562 Perturb-seq dataset has known perturbation-gene relationships that could serve as ground truth; no such validation is attempted.

- **The "calibrated confidence scores" claim is unsubstantiated.** The paper describes the confidence scores as "calibrated" (Section 3.3, line 65) without any calibration analysis. The only relevant analysis (Figure S3, described at lines 197–209) measures rank-order consistency between the model's confidence and cosine similarity to ground truth — this evaluates ranking quality (akin to AUC), not calibration (which requires that a score of 0.8 correspond to ~80% probability of correctness). Using "calibrated" is misleading.

### Minor

- **The weight w=1/3 in the Resolution Score is chosen by a "small grid search" with no quantitative results shown** (Section 3.4, line 79). Figure S5 (in appendix) is said to show w variation, but the text only notes that "outliers can be the key clusters." It does not report whether the optimal *resolution* is stable across different choices of w. If the chosen resolution changes with w, the method's objectivity is compromised.

- **No runtime or cost analysis despite efficiency claims.** The conclusion (line 261) claims the method produces annotations "orders of magnitude faster than manual curation," but no wall-clock time or API cost figures are provided for the 10-resolution sweep using GPT-o3. For a method that calls a frontier LLM on every cluster at every resolution, this information is essential for practical adoption.

### Trivial

- **No analysis of LLM output variance for Stage 2 results.** Repeat tests are reported for GPT-4o in Stage 1 (Section 4.3, line 191), but no repeat runs are reported for GPT-o3 in Stage 2. If the LLM gives different annotations on different API calls, the selected resolution could change.

## Nice-to-Haves

- The paper would be strengthened by validating the chosen resolution against a known biological ground truth. For the K562 Perturb-seq data, one could check whether clusters at the chosen resolution better separate known perturbation classes than clusters at alternative resolutions, using metrics like adjusted Rand index against pathway-based cluster assignments.
- A bridging experiment connecting Stage 1 and Stage 2 (e.g., showing that a worse annotation model leads to a worse resolution choice) would strengthen the pipeline's credibility.
- Reporting whether the optimal resolution is stable across the weight w would improve confidence in the method.

## Removed Points

These points are flagged to be removed, treat them with caution:
- "Prompt details relegated to appendix" — Removed per hard rule (parser strips appendix; it exists in the original submission).
- "Missing appendix content" — Removed per hard rule.
- "Stage 1 does not connect to Stage 2" — Removed as a nice-to-have, not a core weakness.
- "ICS and ICD always agree, raising questions about why combine them" — Removed because the paper presents convergence as confirmatory evidence, not a flaw.
- "Silhouette criticism is generic" — Removed; this is the paper's own argumentation about a baseline method.
- "Missing related works" — Removed per protocol (cannot verify external sources).
- Formatting nitpicks and grammar issues — Removed per hard rules (parser artifacts, not author errors).

## Novel Insights

The harsh critic's core observation — that the paper's central claim of superior resolution selection is asserted but never validated against any biological ground truth — is the key structural insight. The paper essentially proposes a method and demonstrates that it *selects some resolution*, but provides no evidence that this selection is more biologically meaningful than alternatives. Without such validation, the paper reads as a well-motivated method proposal with a useful annotation benchmark, rather than a demonstrated advance in resolution selection. The "comparison" with traditional metrics merely shows disagreement, not superiority.

## Suggestions

1. **Validate the chosen resolution against ground truth.** The K562 Perturb-seq dataset has known perturbation-gene relationships. Define the "correct" resolution as one where clusters separate known perturbation classes (e.g., genes in the same pathway should cluster together), and quantitatively compare HypoGeneAgent's pick against those of silhouette, modularity, and functional enrichment. Even a simple enrichment analysis showing that the chosen resolution's clusters are more enriched for known pathway genes than alternatives would substantially strengthen the paper.

2. **Remove or justify "calibrated."** Unless proper calibration analysis (e.g., reliability diagrams, expected calibration error) is performed, replace "calibrated" with "confidence scores" or "self-assessed confidence scores."

3. **Provide runtime/cost figures.** Report wall-clock time and approximate API costs for the full resolution sweep. This is essential for practical adoption of an LLM-based pipeline.

4. **Show w sensitivity for resolution stability.** Report whether the optimal resolution changes as w varies across [0,1].

## Score and Decision

**Round 1 bracket**: 3.0–5.0. The closest anchor is GenoAgent (4.00, reject), which had similar but less severe evidential gaps (reviewers criticized "experiments not enough" at -9.61; our paper has no ground-truth validation at all for its central claim). Other anchors: LLM4GRN (4.33) mitigated its ground-truth gap with synthetic data validation; scMPT (3.40) had incremental contribution; scROD (3.67) had limited novelty.

**Round 2 narrowing**: Compared itemized impact scores. Our paper has two impact=-10.00 weaknesses (central claim unvalidated, "calibrated" unsupported) vs. GenoAgent's worst at -9.85. GenoAgent's strongest strength (+9.69 for writing, +8.70 for innovation) is comparable to our strongest (+9.85 for novel framing). Our paper is therefore slightly weaker than GenoAgent (4.00), placing it around 3.0–3.5.

**Final score: 3.5**

The paper's central claim — that HypoGeneAgent selects *biologically superior* resolutions — is not supported by the evidence presented. This is an evidential gap that cannot be resolved by minor revisions. However, the core idea is genuinely novel, the metrics are cleanly formalized, and the Stage 1 benchmark is useful. The paper is a reasonable method proposal, but the gap between claims and evidence is too large for acceptance.

MY FINAL SCORE: <score>3.5</score>
MY FINAL DECISION: <decision>Reject</decision>